Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT02224872

Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 
  • Procedure: Bone marrow transplant
    Day 0
  • Drug: Thymoglobulin
    0.5 mg/kg IV on Day -9 2 mg/kg IV on Days -8, -7
  • Drug: Fludarabine
    30 mg/M2 IV on days -6 to -2
  • Drug: Cyclophosphamide
    14.5 mg/kg IV on days -6, -5, 3, 4

    Other Name: CTX
  • Radiation: TBI
    200 cGy on day -1
  • Drug: Mesna
    40 mg/kg IV on days 3, 4
  • Drug: Tacrolimus
    For patients 18 years or older, tacrolimus will be given per institutional standards; may be increased or later changed to a PO BID schedule. Treatment to continue until Day 365 or longer if GVHD present
  • Drug: Mycophenolic acid mofetil
    15 mg/kg PO/IV TID beginning on day 5 through day 35

    Other Name: MMF
Status: 
Recruiting
Study Date: 
Fri, 08/01/2014 to Wed, 08/01/2018
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Intervention: 
Procedure: Bone marrow transplant Day 0 Drug: Thymoglobulin 0.5 mg/kg IV on Day -9 2 mg/kg IV on Days -8, -7 Drug: Fludarabine 30 mg/M2 IV on days -6 to -2 Drug: Cyclophosphamide 14.5 mg/kg IV on days -6, -5, 3, 4 Other Name: CTX Radiation: TBI 200 cGy on day -1 Drug: Mesna 40 mg/kg IV on days 3, 4 Drug: Tacrolimus For patients 18 years or older, tacrolimus will be given per institutional standards; may be increased or later changed to a PO BID schedule. Treatment to continue until Day 365 or longer if GVHD present Drug: Mycophenolic acid mofetil 15 mg/kg PO/IV TID beginning Other Name: MMF